Quince Therapeutics Inc. conducted its Annual Meeting of Stockholders on June 4, 2025, via live webcast. During the meeting, stockholders approved the election of three Class III directors to the Board of Directors. An amendment to the Certificate of Incorporation to increase the total number of authorized common stock shares from 100,000,000 to 250,000,000 was approved. Additionally, an amendment to effect a reverse stock split of the issued and outstanding common stock at a ratio of one-for-ten was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.